Emergent BioSolutions
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.6K
- Market Cap
- -
- Introduction
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units ...
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 100
- Registration Number
- NCT03569553
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 65
- Registration Number
- NCT03315104
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Michael E. DeBakey VA Medical Center, Houston, Texas, United States
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 25
- Registration Number
- NCT03160339
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Vermont Medical Center, Burlington, Vermont, United States
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 20
- Registration Number
- NCT02771730
- Locations
- 🇺🇸
Paxvax, Redwood City, California, United States
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 7
- Registration Number
- NCT02696291
- Locations
- 🇺🇸
Clinical Research Unit, Madison, Wisconsin, United States
VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 3032
- Registration Number
- NCT02443623
- Locations
- 🇨🇦
Bio Products Laboratory Ltd (plasma vendor of Emergent BioSolutions), Winnipeg, Manitoba, Canada
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 573
- Registration Number
- NCT02339155
- Locations
- 🇺🇸
GSK Investigational Site, Knoxville, Tennessee, United States
Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis
- Conditions
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 100
- Registration Number
- NCT02177721
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 64
- Registration Number
- NCT02061358
- Locations
- 🇺🇸
Quintiles, Inc, Overland Park, Kansas, United States
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 162
- Registration Number
- NCT02055183